Profile data is unavailable for this security.
About the company
Iffe Futura SA is a Spain-based company active in the investment industry. The Company is an industrial and financial and education services group. The Company’s business lines are IFFE Business School, DCM Asesores, IFFE Biotech, IFFE Desarrollos and IF. IFFE Business School offers different post-graduate studies and business preparation. DCM Asesores provides advises to the companies in the process of going to MAB (Alternative Stock Market from Spain). IFFE Biotech is a biotechnology company dedicated to the research, development and production of Omega-3 fatty acids. IFFE Desarrollos develops the real estate operations from the Group. IF is the incubator and accelerator of projects and companies of the IFFE Futura Group.
- Revenue in EUR (TTM)45.69m
- Net income in EUR8.80m
- Incorporated2011
- Employees172.00
- LocationNatac Natural Ingredients SAavenida Rita Levi Montalcini n 14GETAFE 28906SpainESP
- Phone+34 881896049
- Websitehttps://www.natacgroup.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Probi AB | 56.57m | 1.21m | 271.76m | 162.00 | 225.35 | 2.18 | 27.29 | 4.80 | 1.20 | 1.20 | 56.41 | 124.20 | 0.4045 | 3.25 | 5.91 | 4,016,925.00 | 0.8624 | 4.64 | 0.9144 | 4.98 | 32.88 | 42.04 | 2.13 | 9.83 | 4.69 | -- | 0.0591 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Themis Medicare Ltd | 44.45m | 5.45m | 273.05m | 1.54k | 50.16 | -- | 40.67 | 6.14 | 5.43 | 5.43 | 44.31 | -- | -- | -- | -- | 2,648,322.00 | -- | 11.12 | -- | 16.46 | 63.51 | 60.32 | 12.26 | 14.96 | -- | -- | -- | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Golden Throat Holdings Group Co Ltd | 129.98m | 33.87m | 274.07m | 860.00 | 8.09 | 1.65 | 7.05 | 2.11 | 0.3893 | 0.3893 | 1.49 | 1.90 | 0.4994 | 3.23 | 4.07 | 1,270,917.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
| IOL Chemicals and Pharmaceuticals Ltd. | 225.70m | 12.91m | 274.94m | 2.78k | 21.29 | -- | 13.65 | 1.22 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Natac Natural Ingredients SA | 45.69m | 8.80m | 276.12m | 172.00 | 51.13 | 6.32 | 17.86 | 6.04 | 0.0124 | 0.0124 | 0.0742 | 0.1004 | 0.4869 | 0.1089 | 9.76 | 315,106.60 | 9.51 | -- | 11.90 | -- | 98.12 | -- | 19.53 | -- | 0.44 | -- | 0.5921 | -- | 3,152.85 | -- | 308.68 | -- | -- | -- |
| Duopharma Biotech Bhd | 159.39m | 10.53m | 282.86m | 1.94k | 26.85 | 1.91 | 13.79 | 1.77 | 0.0514 | 0.0514 | 0.7776 | 0.7214 | 0.5771 | 1.99 | 3.69 | 385,581.40 | 3.81 | 5.54 | 4.62 | 6.91 | 35.98 | 39.77 | 6.61 | 9.49 | 2.93 | 4.03 | 0.4302 | 50.09 | 1.15 | 7.16 | -24.91 | 2.02 | -15.67 | -5.76 |
| Hanshang Group Co Ltd | 169.76m | 2.78m | 285.43m | 2.38k | 98.97 | 1.29 | -- | 1.68 | 0.0757 | 0.0757 | 4.46 | 5.83 | 0.3718 | 2.65 | 8.25 | 552,235.40 | 0.3729 | 2.00 | 0.6192 | 3.89 | 55.85 | 57.24 | 1.00 | 4.89 | 0.2774 | 1.84 | 0.3798 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
| PharmaSGP Holding SE | 109.76m | 18.21m | 285.60m | 93.00 | 15.67 | 8.75 | 10.35 | 2.60 | 1.52 | 1.52 | 9.15 | 2.72 | 0.8223 | 1.04 | 8.57 | 1,233,225.00 | 13.64 | 13.70 | 18.34 | 19.98 | 90.91 | 90.20 | 16.59 | 17.56 | 1.54 | 14.98 | 0.6823 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
Data as of Oct 11 2024. Currency figures normalised to Natac Natural Ingredients SA's reporting currency: Euro EUR
0.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Andbank Wealth Management SGIIC SAUas of 30 Jun 2024 | 1.14m | 0.26% |
| Renta 4 Gestora SGIIC SAas of 31 Dec 2023 | 625.93k | 0.14% |
| GVC Gaesco Gesti�n SGIIC SAas of 31 Mar 2024 | 280.00k | 0.06% |
| Caixabank Asset Management SGIIC SAas of 31 Dec 2023 | 125.00k | 0.03% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
